← Back to patent-cliff list
倍他米松二丙酸酯/卡泊三醇
Tier C — Watch / tradeBetamethasone Dipropionate/Calcipotriol
Mc2 Therapeutics Ltd
Originator
2006
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：GR、VDR
Indications (approved)：斑块银屑病、银屑病
Regional status
US
批准上市
2006-01-09
EU
批准上市
2022-02-22
China
临床三期
2025-12-30
Japan
无进展
2019-01-24
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Betamethasone Dipropionate/Calcipotriol?
Approved indications include: 斑块银屑病, 银屑病.
When does the Betamethasone Dipropionate/Calcipotriol patent expire?
No public expiry year is available for Betamethasone Dipropionate/Calcipotriol yet; this page updates once verified.
How do I get a quote for Betamethasone Dipropionate/Calcipotriol intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24